• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
【24h】

Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.

机译：喹硫平可增强西酞普兰在非难治性强迫症中的作用：一项针对76位患者的随机，双盲，安慰剂对照研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To assess the efficacy of quetiapine addition to citalopram in treatment-naive or medication-free obsessive-compulsive disorder (OCD) patients. METHOD: Seventy-six patients who met DSM-IV criteria for OCD and who were drug-free or drug-naive at entry were randomly assigned in a 10-week, double-blind trial with citalopram (60 mg/day) plus quetiapine (300-450 mg/day) or placebo; treatment-refractory OCD patients were excluded. Of the 76 eligible patients, 66 patients completed the trial-31 in the quetiapine and 35 in the placebo group. The change from baseline to endpoint on the total Yale-Brown Obsessive Compulsive Scale (YBOCS) and the response to treatment in the quetiapine addition compared with the placebo addition group were the primary outcome measures. Response was defined as a 35% or greater reduction on the YBOCS and a Clinical Global Impressions-Improvement (CGI-I) score at endpoint of 1 or 2. The study was conducted from November 2003 to June 2005 at the University Medical Centre Utrecht, The Netherlands. RESULTS: As measured by the mean reduction in YBOCS scores following an intent-to-treat, last-observation-carried-forward analysis, quetiapine addition (11.9) was significantly superior to placebo (7.8; p = .009). Quetiapine addition was also significantly superior to placebo on the CGI-I scale, with a mean +/- SD CGI-I score of 2.1 +/- 1.3 versus 1.4 +/- 1.2, respectively (p = .023). Quetiapine addition (N = 22, 69%) was also associated with a significantly greater number of patients responding to treatment compared with placebo addition (N = 15, 41%; p = .019). More patients receiving quetiapine (N = 8) than placebo (N = 2; NS) discontinued treatment due to adverse events. CONCLUSIONS: The combination of quetiapine and citalopram was more effective than citalopram alone in reducing OCD symptoms in treatment-naive or medication-free OCD patients. TRIAL REGISTRATION: www.trialregister.nl Identifier NTR116.
机译：目的：评估喹硫平加西酞普兰对初治或无药物治疗的强迫症（OCD）患者的疗效。方法：将符合DSM-IV强迫症标准且入院时未吸毒或未吸毒的76例患者随机分为一项为期10周，双盲试验的西酞普兰（60 mg /天）加喹硫平（ 300-450 mg / day）或安慰剂;排除了难治性强迫症患者。在76名合格患者中，有66位患者完成了喹硫平试验（31位），安慰剂组完成了35位。主要的结局指标是总耶鲁-布朗强迫症量表（YBOCS）从基线到终点的变化以及喹硫平组与安慰剂组相比对治疗的反应。缓解定义为YBOCS降低35％或更高，终点为1或2时临床总体印象改善（CGI-I）得分。该研究于2003年11月至2005年6月在乌得勒支大学医学中心进行，荷兰人。结果：根据意向性治疗，最后观察进行的分析后YBOCS评分的平均降低，喹硫平的添加量（11.9）明显优于安慰剂（7.8; p = .009）。在CGI-I量表上，喹硫平的添加也显着优于安慰剂，平均+/- SD CGI-I评分分别为2.1 +/- 1.3和1.4 +/- 1.2（p = .023）。与安慰剂组相比，添加喹硫平（N = 22，69％）与对治疗有反应的患者数量显着增加（N = 15，41％; p = .019）。因不良事件而终止治疗的喹硫平（N = 8）患者比安慰剂（N = 2; NS）患者多。结论：喹硫平和西酞普兰的组合比单独使用西酞普兰在减少未经治疗或无药物治疗的强迫症患者中的强迫症症状更有效。试用注册：www.trialregister.nl标识符NTR116。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号